Argos Therapeutics, a biotechnology company previously known as Merix Bioscience, three-quarters of way through $6m funding round.
Argos Therapeutics, a biotechnology company previously known as Merix Bioscience, has raised $4.85m from 27 undisclosed investors in the first close of its latest funding round.
The round is expected to close at $6m, according to a regulatory filing first reported by news provider TechJournal South.
Argos closed its series C round in November 2008 at $35.2m led by venture capital (VC) firm TVM Capital. Others in the C round were Asia-based VCs Mizuho Capital, Morningside Group and…
